{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.840","upperLimit":"0.990","value":"0.912"}]}],"title":"Irinotecan"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.997","upperLimit":"1.28","value":"1.13"}]}],"title":"SN-38"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Cmax was observed directly from data. The ratio between geometric LS mean (within Cohort 1) for Cmax on Cycle 1 Day 15 and geometric LS mean (within Cohort 1) for Cmax on Cycle 1 Day 1 for irinotecan and its metabolite SN-38 has been presented in this outcome measure, which explains the data reported for this outcome measure using measure type as \"Number\".","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received encorafenib 300 milligrams (mg) once daily (QD) orally (received after Cycle 1 Day 3) and cetuximab 500 mg per square meters (mg/m\\^2) intravenous (IV) infusion for 120 minutes once every 2 weeks (Q2W) along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 180 mg/m\\^2 as IV infusion for 90 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"SLI: Cohort 1 [EC + FOLFIRI]"}],"paramType":"NUMBER","populationDescription":"The PK parameter analysis set was analyzed. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. Participants received irinotecan in Cohort 1 of SLI, hence data is reported only for Cohort 1 and not for Cohort 2.","reportingStatus":"POSTED","timeFrame":"Cohort 1: Pre-dose (0 hr), 0.75, 1.5, 2.5, 3.5, 5.5, 7.5, and 48 hrs post-dose on Days 1 and 15 of Cycle 1","title":"SLI, Cohort 1: Ratio of Cmax on Cycle 1 Day 15 as Compared to Cycle 1 Day 1 for Irinotecan and Its Metabolite SN-38","type":"SECONDARY","unitOfMeasure":"Ratio"}